KDM1A and cancer: For these reasons, the recent entry of KDM1A pharmaco-inhibitors into cancer clinical trials herald a new step in the translation of innovative epigenetic therapies to the clinic (105), even though some of the trials were terminated due to no beneficial effects in the cancer types treated.